257 related articles for article (PubMed ID: 34931528)
1. Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany.
Ziemssen T; Kurzeja A; Muresan B; Haas JS; Alexander J; Driessen MT
Neurodegener Dis Manag; 2022 Apr; 12(2):93-107. PubMed ID: 34931528
[TBL] [Abstract][Full Text] [Related]
2. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
[TBL] [Abstract][Full Text] [Related]
3. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
4. Incidence of type 2 diabetes, cardiovascular disease and chronic kidney disease in patients with multiple sclerosis initiating disease-modifying therapies: Retrospective cohort study using a frequentist model averaging statistical framework.
Brnabic AJM; Curtis SE; Johnston JA; Lo A; Zagar AJ; Lipkovich I; Kadziola Z; Murray MH; Ryan T
PLoS One; 2024; 19(3):e0300708. PubMed ID: 38517926
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
Soini E; Joutseno J; Sumelahti ML
Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis.
Zagmutt FJ; Carroll CA
Int J Neurosci; 2015; 125(11):798-807. PubMed ID: 25387069
[TBL] [Abstract][Full Text] [Related]
7. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis.
Earla JR; Li J; Hutton GJ; Bentley JP; Aparasu RR
Mult Scler Relat Disord; 2024 May; 85():105539. PubMed ID: 38574721
[TBL] [Abstract][Full Text] [Related]
8. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017.
Vermersch P; Suchet L; Colamarino R; Laurendeau C; Detournay B
Mult Scler Relat Disord; 2020 Nov; 46():102521. PubMed ID: 32977077
[TBL] [Abstract][Full Text] [Related]
9. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
English C; Aloi JJ
Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
Braune S; Grimm S; van Hövell P; Freudensprung U; Pellegrini F; Hyde R; Bergmann A;
J Neurol; 2018 Dec; 265(12):2980-2992. PubMed ID: 30327931
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
12. Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register.
Zanghì A; Avolio C; Amato MP; Filippi M; Trojano M; Patti F; Amico E;
Mult Scler Relat Disord; 2022 Feb; 58():103489. PubMed ID: 35032879
[TBL] [Abstract][Full Text] [Related]
13. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
14. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
Kalincik T; Kubala Havrdova E; Horakova D; Izquierdo G; Prat A; Girard M; Duquette P; Grammond P; Onofrj M; Lugaresi A; Ozakbas S; Kappos L; Kuhle J; Terzi M; Lechner-Scott J; Boz C; Grand'Maison F; Prevost J; Sola P; Ferraro D; Granella F; Trojano M; Bergamaschi R; Pucci E; Turkoglu R; McCombe PA; Pesch VV; Van Wijmeersch B; Solaro C; Ramo-Tello C; Slee M; Alroughani R; Yamout B; Shaygannejad V; Spitaleri D; Sánchez-Menoyo JL; Ampapa R; Hodgkinson S; Karabudak R; Butler E; Vucic S; Jokubaitis V; Spelman T; Butzkueven H
J Neurol Neurosurg Psychiatry; 2019 Apr; 90(4):458-468. PubMed ID: 30636699
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study.
Kresa-Reahl K; Repovic P; Robertson D; Okwuokenye M; Meltzer L; Mendoza JP
Clin Ther; 2018 Dec; 40(12):2077-2087. PubMed ID: 30470580
[TBL] [Abstract][Full Text] [Related]
16. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
Thomas RH; Wakefield RA
Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
[TBL] [Abstract][Full Text] [Related]
17. The Patient and Clinician Assessment of Gastrointestinal (GI) Related Adverse Events Associated with Oral Disease-Modifying Therapies in Multiple Sclerosis: A Qualitative Study.
Jivraj F; Kang S; Reedie S; Kapadia S; Strzok S; Elliott E; Cano S; Rock M
Adv Ther; 2022 Nov; 39(11):5072-5086. PubMed ID: 36053450
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry.
Hillert J; Tsai JA; Nouhi M; Glaser A; Spelman T
Mult Scler; 2022 Feb; 28(2):237-246. PubMed ID: 34080926
[TBL] [Abstract][Full Text] [Related]
19. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]